Literature DB >> 22570939

Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits.

Wenli Zhang1, Jin Li, Jianping Liu, Zimei Wu, Yiming Xu, Ji Wang.   

Abstract

Spherical and discoidal tanshinone IIA-loaded reconstituted high density lipoproteins (TA-rHDL) with different formulations and techniques were prepared and characterized. The targeting mechanism was investigated using a foam cell model. Pharmacokinetics of four TA-rHDL formulations with or without apolipoproteins (apos) after a single dose intravenous injection to rabbits has been studied. The results showed that the sizes of spherical and discoidal TA-rHDL increased after coupling with apos from 55.38 nm to 157.26 nm, 61.03 nm to 166.19 nm, and zeta potential decreased from -29.2 mV to -35.4 mV, -5.2 mV to -11.82 mV, respectively. The results of circular dichroic spectroscopy indicated variations of apos in protein secondary structure after binding with lipids. Phagocytosis tests demonstrated that the spherical TA-rHDL had a targeting effect for foam cells through the scavenger receptor-BI and CE-TG interchange with TG-rich lipoproteins pathway under cholesteryl ester transfer protein. Discoidal TA-rHDL could reconstruct to spheres and target via a similar route as TA-rHDL spheres, showing a higher targeting efficiency. In vivo experiments showed that areas under the plasma level-time curve (AUC) of TA increased as a function of spherical and discoidal rHDL, which were 4 and 13 times more than that of TA suspensions, respectively. Spherical and discoidal TA-rHDL had long circulating times in blood with mean residence time (MRT) of 15.874 and 18.956h, respectively, compared to 1.802h of TA suspensions, 14.190h of spherical TA-rHDL without apos and 15.071 of discoidal TA-rHDL without apos. The distribution volume of spherical TA-rHDL was 2.143 and 1.552 times as that of discoidal TA-rHDL and TA suspensions, respectively. In conclusion, TA-rHDL may be a long-circulating, healthy and potentially targeted carrier for delivering lipophilic cardiovascular drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22570939

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  5 in total

1.  Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein.

Authors:  Hongliang He; Mengyuan Zhang; Lisha Liu; Shuangshuang Zhang; Jianping Liu; Wenli Zhang
Journal:  Pharm Res       Date:  2015-06-04       Impact factor: 4.200

Review 2.  Learning from biology: synthetic lipoproteins for drug delivery.

Authors:  Huang Huang; William Cruz; Juan Chen; Gang Zheng
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-10-24

3.  An attempt to stabilize tanshinone IIA solid dispersion by the use of ternary systems with nano-CaCO3 and poloxamer 188.

Authors:  Hong-Mei Yan; Zhen-Hai Zhang; Yan-Rong Jiang; Dong-Mei Ding; E Sun; Xiao-Bin Jia
Journal:  Pharmacogn Mag       Date:  2014-04       Impact factor: 1.085

Review 4.  HDL as a drug and nucleic acid delivery vehicle.

Authors:  Andras G Lacko; Nirupama A Sabnis; Bhavani Nagarajan; Walter J McConathy
Journal:  Front Pharmacol       Date:  2015-10-26       Impact factor: 5.810

Review 5.  Reconfiguring Nature's Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents.

Authors:  Skylar T Chuang; Siobanth Cruz; Vasanthy Narayanaswami
Journal:  Nanomaterials (Basel)       Date:  2020-05-08       Impact factor: 5.076

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.